’res of the authentic McCoy, you’ll discover how to name genuine collectibles in order to t’reasu’res away from low priced garbage. You’ll furthermo’re expand your experience with contextual tale, that is never a terrible thing in order to produces and his awesome conversation.
Back by popular demand! The Conejo Valley Wineries will be hosting our 2nd annual Wine 'N Roses event next Saturday and Sunday, February 11-12. While supplies last, for every paid wine tasting we will offer one long stem rose. Go to all five participating wineries to collect a bouquet!
Participating Wineries: Sunland Vintage, DeLiese Cellars, Giessinger Winery, Nabu, and Alma Sol Winery.This study is a randomized pilot/pharmacodynamic/genomic study of neoadjuvant paricalcitol to target the microenvironment in resectable pancreatic cancer to determine the effect of targeting the vitamin D metabolic program in the tumors of patients treated with one cycle of gemcitabine/abraxane with or without paricalcitol prior to surgery for resectable pancreatic cancer through an assessment of cellular and imaging markers.
Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
Patients with hypercalcemia (blood levels greater than 11.5 mg/dL; in patients with kidney disease, blood calcium levels must be 9.5 mg/dL or lower before starting paricalcitol).
Promoting numerical simulation and HPC is one of the three main missions of GENCI since 2007.
The Conférence des Présidents d’Universités (CPU), GENCI and the Maison de la Simulation lead together the HPC competence label called C3I (Certificat de Compétences en Calcul Intensif).
This label is awarded by a jury composed of research and industry representatives, to doctors who have acquired some competences in HPC during their PhD and optionally during their post-doctorate.
The C3I label concerns all the scientific domains, from theoretical to applied research. The applicant must have acquired competences to use and implement HPC (optimization and parallelization of computation codes, parallel algorithmic, big data management…). This label is awarded in order to increase the visibility of doctors’ works and give them an additional advantage for their career in the academic or industrial field.
More information: c3i-secretariat@genci.fr
Bull-Fourier award: boosting the development of numerical simulation
Yearly awarded in link with GENCI and Serviware, the Bull-Fourier prize acknowledges a scientist or a research team for their achievements in the field of parallelization of numerical applications.
The first prize is €15 000, the others are allocations of computing time on GENCI supercomputers.
Winners of the last Bull-Fourier awards
2014: Ivan Duchemin - CEA et Xavier Blase - CNRS (1st); Jean-Baptiste Filippi and his team - Université de Corse (2nd)
2012: Jean-Michel Alimi and his team - CNRS (1st) ; Luc Bergé and his team - CEA (2nd) ; Yann-Michel Niquet and his team - CEA (3rd)
2011: Julien Bohbot - IFP Energies Nouvelles
2010: Dimitri Komatitsch - Université de Pau et des pays de l’Adour et Inria (1st); Sébastien Jan - CEA (2nd); Vincent Moureau - Coria (3rd)
2009: Luigi Genovese - ESRF (1st); Gabriel Staffelbach - Cerfacs (2nd); Dimitri Komatitsch - Université de Pau et des pays de l’Adour et Inria (3rd)
More information :<filename>include/sway/ois/keymapping.h<gh_stars>0
#ifndef SWAY_OIS_KEYMAPPING_H
#define SWAY_OIS_KEYMAPPING_H

#include <sway/namespacemacros.h>
#include <sway/types.h>

#include <X11/Xlib.h>

NAMESPACE_BEGIN(sway)
NAMESPACE_BEGIN(ois)

struct KeyMapping {
	KeySym keysym;
	u32_t keycode;
};

NAMESPACE_END(ois)
NAMESPACE_END(sway)

#endif // SWAY_OIS_KEYMAPPING_H
– Showbuzz Daily has the ratings for last night’s edition of WWE NXT 2.0. While viewership numbers were down after last week’s return to the USA Network, the key demo ratings increased.
WWE NXT 2.0 drew an average overnight audience of 551,000 viewers. That dropped from last week’s audience of 612,000 viewers. This was the lowest viewership for WWE NXT on the USA Network in over a year, since January 13, 2021.
(h/t Wrestlenomics’ Brandon Thurston)
NXT saw a slight rating increase in the P18-49 key demo with a 0.13. That’s higher than last week’s key demo rating of 0.12. It’s also above the NXT Vengeance Day special airing, which drew a 0.11 rating. That show aired on SyFy Channel last month.
WWE NXT 2.0 ranked No. 70 in the Cable Top 150 rankings for Tuesday. Despite the ratings increase, the show dropped from its No. 43 slot last week. Cable TV coverage was dominated by the telecasts for President Joe Biden’s State of the Union address. So, while WWE NXT was outside the Top 50, there was a lot of competition on the cable news stations last night with the State of the Union coverage dominating the ratings.
CNN’s Coverage of the State of the Union telecast topped the key demo ratings for Tuesday with a 1.17. The FOX News Channel broadcast of the State of the Union Address topped the viewership for the night with 7.206 million viewers.
Telecasts of the State of the Union address and related coverage across broadcast and cable dominated Tuesday night, as expected.
NXT finished somewhere below the top 50 in P18-49 for the day. Showbuzz should have it soon.
Correction/clarification to my first tweet: This was the lowest total viewership for NXT on USA in more than a year, since January 13, *2021*.
NXT ranked #70 in P18-49 for Tuesday against strong competition.I consent to the processing of my personal data and trust that your company will process these in accordance with the General Data Protection Regulation 679/2016 / EU, solely to the extent and for the purpose that I define with my request in order to provide the most appropriate service that I have requested. I also agree that the information I provide through this site can be collected and processed for communication purposes. Furthermore, I consent to your keeping a record of my correspondence and personal data that takes place in accordance with your Company's Privacy Policy as posted on your site.MANILA, Philippines — The Philippines has so far administered more than 17 million COVID-19 doses since the government rolled out its vaccination campaign in March, the Department of Health (DOH) said Monday.
Vaccine statistics released by the DOH revealed that as of July 25, a total of 17,202,421 doses have already been administered.
A total of 11,113,107 individuals have received their first doses while 6,089,314 have already completed their shots.
In the first priority sector (healthcare workers), a total of 1,945,838 were given the first dose while 1,396,737 received their second doses.
In the A2 sector, 1,600,558 senior citizens have completed their doses while 2.836,224 got their first shot.
In the A3 group, a total of 2,050,279 persons with co-morbidities have received their second dose while 3,617,104 got their first jab.
The number of Indigents (A5) who received their first dose reached 425,082 while 229,599 received their second jab.
The DOH said that the average daily administered doses in the last seven days have reached 300,880.
The average number of active reporting vaccination sites in the past week was at 1,355.
The Philippine government has been eyeing to vaccinate up to 70 million people this year to achieve population protection against COVID-19.
The DOH reminded the public to continue following the minimum health public standards to prevent the spread of coronavirus disease and get themselves vaccinated as scheduled.
“Also, let’s get vaccinated when it’s our turn and get the second dose as scheduled. Together, we can beat COVID